Skip to main content
♕ The Globe and Mail Trade Off
Canada's free stock market contest is live! Test your investing skills for a chance to win $5,000.Enter Now!Enter Now!
➜

Novo Nordisk A/S ADR(NVO-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low38.17
Day High38.85
Open:38.58
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

TOP STORIES: Novo Nordisk A/S ADR

Select a category then submit the form to load news
Motley Fool
Down but Not Out: Is Novo Nordisk a Conditional Buy as Eli Lilly Leads the GLP‑1 Market?
Zacks Investment Research
Roche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal
Roche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal
Motley Fool
Novo Nordisk's Obesity Setback: What Kagrama's Miss vs. Zepbound Means for Investors
Tipranks
Barclays Sticks to Their Hold Rating for Novo Nordisk (0QIU)
Tipranks
Novo Nordisk (0QIU) was downgraded to a Hold Rating at Goldman Sachs
Tipranks
Novo Nordisk (NVO) was upgraded to a Hold Rating at Morgan Stanley
Motley Fool
Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?
Tipranks
Novo Nordisk Employees Elect New Board Representatives Ahead of March AGM
Tipranks
Novo Nordisk Details Progress of 2026 Share Buyback Programme
Motley Fool
Unexpected Stock Picks and Looking to the Future
Motley Fool
Why I'm Not Worried About Novo Nordisk Stock
Zacks Investment Research
Pfizer Stock: Buy, Sell or Hold After Its 11% Rally So Far in 2026?
Pfizer Stock: Buy, Sell or Hold After Its 11% Rally So Far in 2026?
Tipranks
Novo Nordisk Advances New First‑in‑Human Obesity Drug NNC6989‑0001 Into Testing
Tipranks
Novo Nordisk (0QIU) Receives a Hold from Barclays
Motley Fool
Got $5,000? Hims & Hers Could Be a Direct‑to‑Consumer Health Moonshot in the Making
Motley Fool
Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play
Motley Fool
Why Shares of Novo Nordisk Stock Sank (Again) This Week
Motley Fool
Hims & Hers: The Telehealth Growth Story Younger Investors Can't Afford to Ignore
Motley Fool
Stock Market Today, Feb. 25: Novo Nordisk Dips After Announcing $2.1 Billion Partnership With Vivtex for Oral Drug-Delivery Technologies
Motley Fool
Eli Lilly Just Took 2 Major Steps Forward in the Billion-Dollar Obesity Drug Market. Here's What You Need to Know.
Motley Fool
1 Reason Why I'd Hold This Weight‑Loss Drug Leader Through Any Market Crash
Tipranks
Wedbush says Anthropic demos strong, software-replacement hype overdone
Tipranks
BofA sees limited impact to Eli Lilly’s franchise from Novo’s GLP-1 price update
Tipranks
Jefferies Keeps Their Hold Rating on Novo Nordisk (0QIU)
Tipranks
BMO Capital Remains a Hold on Novo Nordisk (NVO)
Motley Fool
Could Novo Nordisk Help Turn $100,000 Into $1 Million in the GLP‑1 Gold Rush?
Motley Fool
Why Eli Lilly Stock Slumped Today
Tipranks
Novo Nordisk (0QIU) was downgraded to a Hold Rating at Deutsche Bank
Tipranks
Novo Nordisk Advances DKK 15 Billion Share Buyback, Lifts Treasury Stake to 0.5%
Tipranks
Novo Nordisk (0QIU) Receives a Hold from Barclays
Tipranks
Goldman Sachs Keeps Their Buy Rating on Novo Nordisk (0QIU)
Tipranks
Novo Nordisk’s CagriSema Misses Non‑Inferiority Goal but Delivers 23% Weight Loss in REDEFINE 4 Trial

Profile

Bagsv'rd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market. The company is also a key player in hemophilia care, growth hormone therapy, hormone replacement therapy and obesity.Novo Nordisk operates through two segments: Diabetes and obesity care and Biopharmaceuticals. While the Diabetes and obesity care segment covers insulins, glucagon-like peptide 1 (GLP-1), other protein-related products, obesity and oral anti-diabetic drugs, the Biopharmaceuticals segment includes hemophilia, growth hormone therapy and hormone replacement therapy.Novo Nordisk's most well-known drugs include Levemir, NovoRapid, Victoza, Ozempic, NovoMix, NovoSeven, NovoThirteen, Ryzodeg, Xultophy, Saxenda, Rybelsus, Esperoct, Sogroya and Norditropin, among several others. The company launched its first product for weight management, Saxenda, in the United States in 2015.In August 2018, Novo Nordisk announced that it has acquired all of the shares of Ziylo Ltd.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.